1-(4-氯苯基)-2,5-二甲基-1H-吡咯-3-羧酸 | 60217-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 1-(4-氯苯基)-2,5-二甲基-1H-吡咯-3-羧酸
• 英文名称: 1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrole-3-carboxylic acid
• 英文别名: 1-(4-chlorophenyl)-2,5-dimethylpyrrole-3-carboxylic acid
• CAS: 60217-76-7
• 化学式: C₁₃H₁₂ClNO₂
• mdl: MFCD00177046
• 分子量: 249.697
• InChiKey: CCMUJMMWBQLMFO-UHFFFAOYSA-N

物化性质

• 沸点：
  414.9±45.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  2-乙酰基-4-戊酮酸乙酯 在 lithium hydroxide monohydrate 、 水 、 对甲苯磺酸 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 48.0h， 生成 1-(4-氯苯基)-2,5-二甲基-1H-吡咯-3-羧酸
  参考文献：
  名称：

  Screening of a Custom-Designed Acid Fragment Library Identifies 1-Phenylpyrroles and 1-Phenylpyrrolidines as Inhibitors of Notum Carboxylesterase Activity

  摘要：

  The Wnt family of proteins are secreted signaling proteins that play key roles in regulating cellular functions. Recently, carboxylesterase Notum was shown to act as a negative regulator of Wnt signaling by mediating the removal of an essential palmitoleate. Here we disclose two new chemical scaffolds that inhibit Notum enzymatic activity. Our approach was to create a fragment library of 250 acids for screening against Notum in a biochemical assay followed by structure determination by X-ray crystallography. Twenty fragments were identified as hits for Notum inhibition, and 14 of these fragments were shown to bind in the palmitoleate pocket of Notum. Optimization of 1-phenylpyrrole 20, guided by structure-based drug design, identified 20z as the most potent compound from this series. Similarly, the optimization of 1-phenylpyrrolidine 8 gave acid 26. This work demonstrates that inhibition of Notum activity can be achieved by small, drug-like molecules possessing favorable in vitro ADME profiles.

  DOI：

  10.1021/acs.jmedchem.0c00660

文献信息

• PRODRUGS OF INHIBITORS OF PLASMA KALLIKRIEN
  申请人：Sinha Sukanto

  公开号：US20110152533A1

  公开（公告）日：2011-06-23

  The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:

  该发明提供了抑制血浆激肽酶（PK）活性的化合物的前体药物，以及预防和治疗血浆激肽酶依赖性疾病或病况的方法，例如糖尿病黄斑水肿，这些前体药物具有以下结构式：
• PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20100256126A1

  公开（公告）日：2010-10-07

  The present application relates to compounds of formula wherein the definitions are as described herein. The present compounds are high potential NK-3 receptor antagonists that are useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本申请涉及以下式子的化合物，其中定义如本文所述。这些化合物是高潜力的NK-3受体拮抗剂，可用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）。
• PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN
  申请人：ActiveSite Pharmaceuticals, Inc.

  公开号：US20140128436A1

  公开（公告）日：2014-05-08

  The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:

  本发明提供了抑制血浆卡利肌酶（PK）活性的化合物的前药，并提供了预防和治疗依赖于血浆卡利肌酶的疾病或情况的方法，例如糖尿病黄斑水肿。这些前药的化学式为：
• Screening of a Custom-Designed Acid Fragment Library Identifies 1-Phenylpyrroles and 1-Phenylpyrrolidines as Inhibitors of Notum Carboxylesterase Activity
  作者：William Mahy、Mikesh Patel、David Steadman、Hannah L. Woodward、Benjamin N. Atkinson、Fredrik Svensson、Nicky J. Willis、Alister Flint、Dimitra Papatheodorou、Yuguang Zhao、Luca Vecchia、Reinis R. Ruza、James Hillier、Sarah Frew、Amy Monaghan、Artur Costa、Magda Bictash、Magnus W. Walter、E. Yvonne Jones、Paul V. Fish

  DOI：10.1021/acs.jmedchem.0c00660

  日期：2020.9.10

  The Wnt family of proteins are secreted signaling proteins that play key roles in regulating cellular functions. Recently, carboxylesterase Notum was shown to act as a negative regulator of Wnt signaling by mediating the removal of an essential palmitoleate. Here we disclose two new chemical scaffolds that inhibit Notum enzymatic activity. Our approach was to create a fragment library of 250 acids for screening against Notum in a biochemical assay followed by structure determination by X-ray crystallography. Twenty fragments were identified as hits for Notum inhibition, and 14 of these fragments were shown to bind in the palmitoleate pocket of Notum. Optimization of 1-phenylpyrrole 20, guided by structure-based drug design, identified 20z as the most potent compound from this series. Similarly, the optimization of 1-phenylpyrrolidine 8 gave acid 26. This work demonstrates that inhibition of Notum activity can be achieved by small, drug-like molecules possessing favorable in vitro ADME profiles.
• US8324250B2
  申请人：——

  公开号：US8324250B2

  公开（公告）日：2012-12-04